MY207205A - Cd3 antibody and pharmaceutical use thereof - Google Patents

Cd3 antibody and pharmaceutical use thereof

Info

Publication number
MY207205A
MY207205A MYPI2021002766A MYPI2021002766A MY207205A MY 207205 A MY207205 A MY 207205A MY PI2021002766 A MYPI2021002766 A MY PI2021002766A MY PI2021002766 A MYPI2021002766 A MY PI2021002766A MY 207205 A MY207205 A MY 207205A
Authority
MY
Malaysia
Prior art keywords
antibody
cells
tumor
present disclosure
pharmaceutical use
Prior art date
Application number
MYPI2021002766A
Inventor
Weikang Tao
Hua Ying
Ling Zhang
Xiaoying Yang
Hu Ge
Original Assignee
Shanghai hengrui pharmaceutical co ltd
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai hengrui pharmaceutical co ltd, Jiangsu Hengrui Medicine Co filed Critical Shanghai hengrui pharmaceutical co ltd
Publication of MY207205A publication Critical patent/MY207205A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present disclosure relates to a CD3 antibody and a pharmaceutical use thereof. Specifically, the present disclosure relates to forming a multi-specificity antibody by using CD3 antibody and binding molecules of another target. The multi-specificity antibody may simultaneously bind to CD3 and another tumor-associated antigen, and bind and activate CD3-positive T cells while binding tumor-associated antigen-expressing cells, thereby promoting T cells specifically killing tumor cells that express tumor-associated antigens. In addition, the present disclosure also provides a preparation and application of a multi- specific antibody. (FIGURE 1A)
MYPI2021002766A 2018-12-07 2019-12-06 Cd3 antibody and pharmaceutical use thereof MY207205A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811491781 2018-12-07
PCT/CN2019/123548 WO2020114478A1 (en) 2018-12-07 2019-12-06 Cd3 antibody and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
MY207205A true MY207205A (en) 2025-02-06

Family

ID=70975360

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2021002766A MY207205A (en) 2018-12-07 2019-12-06 Cd3 antibody and pharmaceutical use thereof

Country Status (12)

Country Link
US (1) US12258405B2 (en)
EP (1) EP3892639A4 (en)
JP (1) JP7461950B2 (en)
KR (1) KR102952460B1 (en)
CN (2) CN112955471B (en)
AU (1) AU2019394241B2 (en)
BR (1) BR112021010026A2 (en)
MX (1) MX2021006389A (en)
MY (1) MY207205A (en)
TW (1) TWI821474B (en)
WO (1) WO2020114478A1 (en)
ZA (1) ZA202104518B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7641908B2 (en) * 2019-03-29 2025-03-07 ジエンス ヘンルイ メデイシンカンパニー リミテッド Pharmaceutical composition containing an antibody against IL-5 and its use
TW202325743A (en) * 2021-07-14 2023-07-01 大陸商江蘇恆瑞醫藥股份有限公司 Antigen-binding molecule that specifically binds to cd38, bcma and cd3 and medical uses thereof
CN113527493B (en) * 2021-07-20 2023-10-27 广州爱思迈生物医药科技有限公司 A B7-H3 antibody and its application
EP4397685A4 (en) * 2021-09-03 2025-10-22 Novoprotein Scient Inc HUMANIZED ANTI-CD3 ANTIBODY
CN116462765A (en) * 2022-01-20 2023-07-21 上海君实生物医药科技股份有限公司 Anti-CD3 and anti-CD20 bispecific antibodies and uses thereof
MX2024011128A (en) * 2022-03-14 2024-09-18 Jiangsu Hengrui Pharmaceuticals Co Ltd Antigen-binding molecule specifically binding to gprc5d and cd3 and medical use thereof.
CN115368464B (en) * 2022-07-19 2025-06-10 合肥天港免疫药物有限公司 Bispecific antibodies and their applications
CN115368462B (en) * 2022-07-19 2026-01-02 合肥天港免疫药物有限公司 Bispecific antibodies and their applications
CN115368465B (en) * 2022-07-19 2026-02-24 合肥天港免疫药物有限公司 Bispecific antibodies and uses thereof
KR20260051102A (en) * 2023-07-07 2026-04-15 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 EGFR/C-MET bispecific binding protein and its uses
CN121443647A (en) * 2023-07-07 2026-01-30 四川科伦博泰生物医药股份有限公司 EGFR/c-MET Bispecific Binding Protein and Its Uses
CN119569886A (en) * 2023-09-06 2025-03-07 合肥天港免疫药物有限公司 Bispecific antibodies and uses thereof
WO2025056013A1 (en) * 2023-09-13 2025-03-20 江苏恒瑞医药股份有限公司 Pharmaceutical composition comprising bispecific antibody specifically binding to gprc5d and cd3
CN122161833A (en) * 2023-11-15 2026-06-05 四川科伦博泰生物医药股份有限公司 Antibody-drug conjugates targeting EGFR/c-MET, their preparation methods and applications
WO2025131024A1 (en) * 2023-12-22 2025-06-26 江苏恒瑞医药股份有限公司 Pharmaceutical composition comprising bispecific antibody specifically binding dll3 and cd3
WO2025245264A1 (en) * 2024-05-21 2025-11-27 Briapro Therapeutics Corp. Anti-b7-h3 antibodies and methods of use thereof
CN122234224A (en) * 2026-05-21 2026-06-19 济南微生态生物医学省实验室 A nanobody targeting PSMA and its application

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
EP2352763B2 (en) * 2008-10-01 2022-09-21 Amgen Research (Munich) GmbH Bispecific single chain antibodies with specificity for high molecular weight target antigens
KR101837053B1 (en) * 2008-10-01 2018-03-12 암젠 리서치 (뮌헨) 게엠베하 Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalphaxcd3 bispecific single chain antibody
WO2012162067A2 (en) * 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
IN2014MN02293A (en) * 2012-04-20 2015-08-07 Emergent Product Dev Seattle
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US10647768B2 (en) * 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
WO2016154585A1 (en) * 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
HK1253512A1 (en) * 2015-05-29 2019-06-21 Amphivena Therapeutics, Inc. Methods of using bispecific cd33 and cd3 binding proteins
TWI744242B (en) * 2015-07-31 2021-11-01 德商安美基研究(慕尼黑)公司 Antibody constructs for egfrviii and cd3
JP2018523686A (en) * 2015-08-17 2018-08-23 マクロジェニクス,インコーポレーテッド Bispecific monovalent diabody capable of binding to B7-H3 and CD3 and uses thereof
MY195059A (en) * 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
EP3356407B1 (en) 2015-10-02 2021-11-03 F. Hoffmann-La Roche AG Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
CN106632681B (en) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 Anti- EGFR and AntiCD3 McAb bispecific antibody and its application
CN106589129B (en) * 2016-12-30 2021-03-05 上海近岸生物科技有限公司 Tri-functional molecule combined with CD19, CD3 and CD28 and application thereof
CN112969476B (en) * 2018-12-07 2024-06-14 江苏恒瑞医药股份有限公司 Multi-specific protein molecules

Also Published As

Publication number Publication date
EP3892639A4 (en) 2022-08-24
KR102952460B1 (en) 2026-04-13
BR112021010026A2 (en) 2021-08-17
CN116396386A (en) 2023-07-07
KR20210100654A (en) 2021-08-17
WO2020114478A1 (en) 2020-06-11
AU2019394241B2 (en) 2026-04-09
ZA202104518B (en) 2023-01-25
TWI821474B (en) 2023-11-11
CN112955471A (en) 2021-06-11
JP7461950B2 (en) 2024-04-04
MX2021006389A (en) 2021-07-15
TW202021987A (en) 2020-06-16
AU2019394241A1 (en) 2021-06-03
US20220242953A1 (en) 2022-08-04
CA3121565A1 (en) 2020-06-11
JP2022510322A (en) 2022-01-26
EP3892639A1 (en) 2021-10-13
CN112955471B (en) 2022-11-22
US12258405B2 (en) 2025-03-25

Similar Documents

Publication Publication Date Title
MX2021006389A (en) Cd3 antibody and pharmaceutical use thereof.
WO2020052692A3 (en) Binding molecules against cd3 and uses thereof
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
MX2022015823A (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof.
PH12018501611A1 (en) Antigen binding proteins thant bind pd-l1
ZA201803079B (en) Anti-dr5 antibodies and methods of use thereof
AU2018253589A1 (en) Antibodies, pharmaceutical compositions and uses thereof
PH12020500667A1 (en) Multispecific antibodies and use thereof
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
MX2020004410A (en) Antibody compositions for tumor treatment.
EP4295918A3 (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
AU2018258045A1 (en) Chimeric antibody/T-cell receptor constructs and uses thereof
EA201990171A1 (en) SPECIFIC ANTIBODY AGAINST EGFR AND AGAINST CD3 AND ITS APPLICATION
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
MY193013A (en) Bispecific antibodies with tetravalency for a costimulatory tnf receptor
WO2013188693A8 (en) Antigen binding constructs to cd3
HUE073077T2 (en) Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
PH12019501089A1 (en) Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
AU2019433019A8 (en) Antibodies binding CD40 and uses thereof
ZA202008095B (en) Humanized antibodies against psma
MX2023004275A (en) Anti-pd-1/cd40 bispecific antibodies and uses thereof.
MX2025002569A (en) Anti-trop2/egfr antibodies and uses thereof
MX2020008730A (en) B7-H4 ANTIBODY DOSING REGIMENS.
MX2024009292A (en) Anti-her2/trop2 antibodies and uses thereof.